Anti-cIAP2/BIRC3 Antibody, clone 1N23 ZooMAb^® Rabbit Monoclonal

We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Clone 1N23 is a ZooMAb^® rabbit recombinant monoclonal antibody that specifically detects cIAP2/BIRC3. It targets an epitope within 23 amino acids from the N-terminal half.

KLH-conjugated linear peptide corresponding to 23 amino acids from the N-terminal half of human Baculoviral IAP repeat-containing protein 3 (cIAP2/BIRC3).

Quality Control Testing

Evaluated by Western Blotting in Raji cell lysate.

Western Blotting Analysis: A 1:10,000 dilution of this antibody detected cIAP2/BIRC3 in Raji cell lysate.

Tested Applications

Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected cIAP2/BIRC3 in Ramos cell lysate.

Affinity Binding Assay: A representative lot of this antibody bound cIAP2/BIRC3 peptide with a KD of 1.0 x 10-12 in an affinity binding assay.

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected cIAP2/BIRC3 in Ramos cells.

Immunohistochemistry (Paraffin) Analysis: A 1:1,000 dilution from a representative lot detected cIAP2/BIRC3 in human testis tissue sections.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Baculoviral IAP repeat-containing protein 3 (UniProt: Q13489; also known as EC:2.3.2.27, Apoptosis inhibitor 2, API2, Cellular inhibitor of apoptosis 2, C-IAP2, IAP homolog C, Inhibitor of apoptosis protein 1, hIAP-1; hIAP1, RING finger protein 49, RING-type E3 ubiquitin transferase BIRC3, TNFR2-TRAF-signaling complex protein 1) is encoded by the BIRC3 (also known as API2, MIHC, RNF49) gene (Gene ID: 330) in human. cIAP2/BIRC3 is a multi-functional zinc-binding protein that regulates the activity of caspases and apoptosis and modulates inflammatory signaling and immunity, cell proliferation, invasion, and metastasis. It acts as an E3 ubiquitin-protein ligase and regulates NF-kB signaling by acting as a positive regulator of the canonical pathway and suppresses constitutive activation of non-canonical NF-kB signaling. Via its E3 ubiquitin-protein ligase activity it can target RIP kinase 1, 2, 3, and 4, caspase 3, 7, 8,  and TRAF1, and BCL10. cIAP2/BIRC3 contains three baculoviral IAP repeat (BIR) domains (aa 29-96; 169-235; 255-322) that are involved in protein-protein interactions. Each BIR domain contains of 66-67 amino acids, whose fold is stabilized by a zinc atom that is coordinated by one histidine and three cysteine residues. It also has a caspase recruitment (CARD) domain (aa 439-529) and a C-terminal Ring zinc-finger domain (aa 557-592). Its high expression is observed in fetal lung and kidney. In the adult, its expression is mainly observed in lymphoid tissues. cIAP2/BIRC3 plays a role as a tumor suppressor and its deficiency is associated with poor prognosis and resistance to chemotherapy.  Mutations in BIRC3 gene or its deletion is reported in some cases of chronic lymphocytic leukemia (CLL). This ZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, Affinity^™, reproducibility, and stability over conventional monoclonals. (Ref.: Frazzi, R. (2021). Cell Biosci. 11; Article 8; Bertrand, MJM., et al. (2011). PLoS One 6(9); e22356).

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Affinity is a trademark of Mine Safety Appliances Co.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.